Clinical Trial Update: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating daprodustat (a prolyl hydroxylase inhibitor) for anemia in non-dialysis CKD patients; completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 3 | Status: COMPLETED | Results posted: 2021-11-03